1. Introduction {#s0005}
===============

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by sustained pulmonary arterial vasoconstriction and vascular remodeling ultimately leading to right ventricular failure and death. The pathophysiology of PAH in complex and involves abnormal proliferation of the vascular smooth muscle and endothelial cells, infiltration by the inflammatory cells, and fibrosis of the vascular elements [@bib20] Multiple factors including endothelial dysfunction with reduced NO bioavailability, increased production of reactive oxygen species (ROS), impaired synthesis of prostaglandin with PGI~2~ deficiency and excessive production of various mediators (angiotensin II, endotelin-1, etc.) play role in the pathologic remodeling of the pulmonary vasculature [@bib1]. Recently, the action of the inflammatory, procoagulant, antiapoptotic, and autoimmune mediators, as well as cell--cell and cell--matrix interactions have been recognized as important contributors to disease progression [@bib66]. Despite the progress in understanding PAH and major advances in its treatment the prognosis of the disease still remains unfavorable with the mortality rate of 10--15% per year and median survival of approximately 7 years [@bib5], [@bib25] underscoring the need for more effective therapeutic options.

Currently approved PAH specific therapies include prostacyclins, phosphodiesterase inhibitors, endothelin receptor antagonists, and soluble guanylyl cyclase agonists [@bib21]. Impaired synthesis of prostacyclin from arachidonic acid was the first pathobiological mechanism described in PAH, which pioneered effective drug development [@bib12]. Reduced expression of prostacyclin synthase (PGIS) was found in pulmonary arteries in PAH patients [@bib67], and peroxynitrite-mediated nitration of specific protein tyrosine residues was shown to be responsible for selective inactivation of PGIS and development of endothelial dysfunction [@bib14], [@bib81].

Increased production of ROS and oxidative stress (OS) are the major contributors to the disorders in the [l]{.smallcaps}-arginine-NO-signaling pathway with changes in NO synthase (NOS) activity and NO deficiency and impaired pulmonary vasodilatory responses being characteristic features of PAH [@bib23]. The underlying mechanisms of the derangements in NO synthesis are related either to the oxidative loss of NOS cofactor tetrahydrobiopterin (BH4) or oxidative attack on the zinc tetrathiolate cluster, which is an important mediator for the NOS dimeric structure [@bib1]. Moreover, increased nonenzymatic NO production in hypoxic and oxidative environment rather promotes formation of peroxinitrite than improves NO bioavailability.

OS is commonly recognized player at the field of PAH. Signs of OS with excessive lipid peroxidation were demonstrated in PAH patients by increased levels of isoprostanes in urine [@bib13] and malondialdehyde in plasma [@bib32]. The other product of lipid peroxidation is hydroxynonenal (HNE). It is regarded not only as a useful marker of oxidative inflammatory condition but also exerts a wide range of pathophysiological effects, including synthesis and release of vasoactive mediators, breakdown of the endothelial barrier function and induction of the pro-inflammatory phenotype within the vessel wall making the study of HNE role in PAH particularly important [@bib7]. The opposing effects of HNE on the NO homeostasis have been described [@bib56], although the data on its role in PAH is missing.

Changes in the fatty acid (FA) composition were shown to interfere with NO signaling. NO production can be stimulated by the polyunsaturated FA (PUFA) such as arachidonic, eicosapentanoic (EPA), and docosahexanoic (DHA) acids [@bib3], [@bib39], [@bib43]. This relationship is bidirectional as inhibition of NO synthesis was demonstrated to increase erythrocyte membrane fluidity due to the higher content of the unsaturated FAs [@bib16], while administration of [l]{.smallcaps}-arginine increased levels of linoleic (LA), γ-linolenic acid (GLA) and dihomo-GLA [@bib45]. Increased levels of free FAs in blood have been closely linked to endothelial dysfunction and altered eNOS activity attributed to the impaired action of the phospholipase C activating receptor agonists (such as acetylcholine, ATP, bradykinin) and reduced \[Ca^2+^\]~i~ increments [@bib17], [@bib64]. Thus, metabolic alterations contributing to the impaired NO bioavailability observed in PAH involve alterations in the FAs status and potentiation of the [l]{.smallcaps}-arginine-NO-system during treatment may be accompanied by changes in the lipid composition.

At present, targeting [l]{.smallcaps}-arginine-NO pathway is a cornerstone strategy in PAH treatment. The approved therapeutic options include sildenafil, tadalafil, and vardenafil -- inhibitors of phosphodiesterase type 5 (PDE-5), and riociguat, which stimulates soluble guanylyl cyclase and promotes cGMP synthesis [@bib21], [@bib55]. Sildenafil has the highest level of evidence in PAH [@bib21]. As the other PDE-5 inhibitors it blocks enzymatic degradation of the second messenger cGMP to GMP, increases intracellular cGMP level and leads to activation of the protein kinase G (PKG) with subsequent relaxation of smooth muscle cells, reduction of vascular remodeling and vasoconstriction. At the same time, precise molecular mechanisms of the protective effects of sildenafil are not completely understood. Recently, it was demonstrated that sildenafil suppressed multiple cytokines involved in neutrophil and mononuclear cell recruitment and reduced NF-kB and p38 MAPK activation in lungs from rats with monocrotaline induced PAH [@bib36]. Moreover, its use caused stimulation of another PDE type 3-PKA pathway and targeted mitochondrial K^+^~ATP~ channels, mitochondria and inflammation in hypertrophied right ventricle in PAH patients [@bib48]. The inhibitory action of sildenafil on the main sources of free radicals production such as xanthine oxidase [@bib63] and NADPH oxidase [@bib47] points to its role as an antioxidant. Thus, the action of sildenafil is not limited to mechanistic inhibition of PDE5-PKG system but also includes modulation of the inflammatory and redox status, which are increasingly recognized as important contributors to PAH progression.

Development of PAH is characterized not only by the defective vasodilator but also exaggerated vasoconstrictor responses. The latter involve activation of the sympathetic nervous system, which was confirmed by the studies of the heart rate variability (HRV) in PAH subjects [@bib6], [@bib71]. Interestingly, that inhibition of NOS in healthy volunteers caused sympathetic activation [@bib76], while administration of PDE-5 inhibitor improved NO bioavailability and prevented hypoxic pulmonary hypertension [@bib42]. There is increasing evidence that HRV is informative not only about the autonomic balance but also reflects the severity of the inflammatory conditions and depth of the oxidative stress [@bib74] which has not been addressed in PAH.

In present study we aimed to assess the effects of sildenafil on the FAs status, level of hydroxynonenal (HNE) and heart rate variability (HRV) in PAH patients. We hypothesize that improvement of NO bioavailability with sildenafil will reduce lipid peroxidation, diminish signs of OS, providing antioxidant effect in PAH patients. Correction of the metabolic disorders at the level of an organism can be reflected by increased HRV and improvement in the balance between autonomic components which influence the heart rhythm.

2. Materials and methods {#s0010}
========================

2.1. Selection of patients and study design {#s0015}
-------------------------------------------

Patients with newly diagnosed PAH (idiopathic, familial or occurring after surgical repair of congenital systemic-to-pulmonary shunts that had been performed at least five years previously) with a six-minute walking distance from 100 m to 450 m were included into the study. PAH was characterized by the presence of pre-capillary PH, i.e., mPAP≥25 mmHg, pulmonary artery wedge pressure ≤15 mmHg by right heart catheterization, in the absence of other causes of pre-capillary PH. Thermodilution method was used for cardiac output measurement. Upon confirmation of PAH sildenafil at a dose of 25 mg three times per day was initiated in addition to the conventional therapies including diuretics and anticoagulants. The duration of the study period was 12 weeks. Patients treated with other PAH specific medications such as inhaled or intravenous prostanoids, endothelin receptor blocker, calcium channel blockers and supplementation with [l]{.smallcaps}-arginine, and fish oil were not included into the study. Patients remained on their usual diet throughout the study. Healthy volunteers comprised a control group. They underwent standard clinical evaluation, blood sampling and HRV measurement once and did not receive any medications. The study was approved by Ethics Committee of the Danylo Halytsky Lviv National Medical University and written informed consent was obtained from all participants.

2.2. Efficacy measures {#s0020}
----------------------

The measures of efficacy included the change in exercise capacity, as measured by the total distance walked in six minutes (6 min walk test, 6MWT), from baseline to week 12, score on the Borg scale of dyspnea (with 0 representing no dyspnea and 10 maximal dyspnea), World Health Organization (WHO) functional class (FC) of PAH. Other measures of efficacy were the changes in the peak pressure gradient of tricuspid regurgitation and right ventricle diameter by echocardiography [@bib20] Physical examinations and laboratory tests were performed before and 12 weeks after initiation of sildenafil therapy. Fasting blood samples were obtained by venepuncture of the cubital vein, centrifuged and serum was stored under −80 °C until the analysis.

2.3. Fatty acids determination {#s0025}
------------------------------

Phospholipid and free FAs were determined by gas chromatography according to the method of Christie [@bib11]. Lipid components were isolated by Folch extraction using chloroform/methanol mixture (2:1, v/v) in the presence of 0.01% butylated hydroxytoluene (BHT). Using TLC, free fatty acids and total phospholipids were separated with the mobile phase heptane--diisopropyl ether--acetic acid (60:40:3, v/v/v). All lipid fractions were transmetylated to fatty acid methyl esters (FAMEs) with boron trifluoride in methanol reagent under nitrogen atmosphere without previous separation from the layer. The FAMEs were analyzed by gas chromatography with a flame ionization detector (FID) on Clarus 500 Gas Chromatograph (Perkin Elmer). Separation of FAMEs was carried out on capillary column coated with Varian CP-Sil88 stationary phase. Operating conditions were as follows: the split--splitless injector was used in split mode with a split ratio of 1:20. The injection volume of the sample was 2 µL. The injector and FID detector temperatures were kept at 260 °C. The column temperature was programmed from 150 °C (2 min) to 230 °C (10 min) at 4 °C/min. The carrier gas was helium at a flow rate of 1 mL/min. 1,2-dinonadecanoyl-*sn*-glycero-3-phosphocholine (19:0 PC) was used as an internal standard. The LOD for FAMEs standards was in the range of 150--250 ng/ml and the LOQ was in the range of 500--700 ng/mL, at a signal-to-noise ratio of 3 and 10, respectively. The precision of LOQ was 7.5% (CV). The linear dynamic range was 500--50000 ng/ml.

2.4. Lipid peroxidation products and NT-proBNP determination {#s0030}
------------------------------------------------------------

4-hydroxynonenal (4-HNE) was assayed as a fluorimetric derivative with 1,3-cyclohexandione (CHD) [@bib75]. Samples were mixed with methanol (1:1, V/V) and centrifuged at 850*g* for 10 min. CHD reagent was added to supernatant and obtained mixture was incubated for 1 h at 60 °C. The samples were purified by using Sep-pak ODS columns (Waters Associates, USA) and eluted with methanol. The eluent was evaporated to dryness under nitrogen and samples were reconstituted in 150 μl of methanol and subjected to HPLC. Chromatographic separation of CHD-adducts was carried out on RP C~18~ column with a linear gradient mobile phase consisted of methanol (MeOH), water and tetrahydrofuran [@bib75]. The HPLC fluorescence detector was used with excitation at 380 nm and emission at 445 nm. The retention time was 20.07 min. The concentration of 4-HNE in the samples was calculated using a calibration curve (625--2000 nmol/l, *R*^2^=0.9997).

Evaluation of the N-terminal natriuretic peptide (NT-proBNP) level in the venous blood was performed by electro-chemiluminesence immunoassay using Roche Diagnostic reagents. The reference values of NT-proBNP for the individual aged 18--44 years are\<85.8 pg/ml for male and\<130 pg/ml for female.

2.5. Study of heart rate variability {#s0035}
------------------------------------

During quiet wakefulness in the morning hours the short time ECG records were obtained using computer electrocardiograph "VNS-Micro" (Neurosoft®, Russia). After 20 min of rest, subjects were asked to stay supine quietly for 5 min for stationary HRV recording; afterwards they were asked to stand up rapidly and remained in the standing position for 6 min (orthostatic test). RR intervals were determined with a sampling frequency of 2 kHz and were analyzed with "Poly-Spectrum" (Neurosoft®, Russia) software designed according to HRV standards [@bib28]. The time-domain indices -- standard deviation of normal RR intervals (SDNN), the square root of the mean squared differences of successive RR interval (RMSSD), and percentage of differences between adjacent normal RR intervals exceeding 50 milliseconds (pNN50) were determined. The power spectral analysis was performed sequentially with a fast Fourier transformation. The following frequency-domain variables were studied: total power (TP, 0.01 to 0.40 Hz), high frequency power (HF, 0.15 to 0.40 Hz), low frequency power (LF, 0.04 to 0.15 Hz), and very low frequency power (VLF, 0.01 to 0.04 Hz).

2.6. Statistical analysis {#s0040}
-------------------------

Data was processed using Microsoft Excel for storage and basic calculations. Statistical calculations were performed by GraphPad Prism (version 5.00, open source). Normal distribution of the obtained data was confirmed with Shapiro--Wilk\'s *W*-test. Data are presented as means±standard deviation (M±SD), median (quartile range), means±standard error mean (M±SEM). The unpaired and paired *t*-test for independent variables was utilized to compare means between groups. The change in Borg dyspnea score was assessed by nonparametric Wilcoxon's matched pairs test. Values of *P*\<0.05 were considered significant.

3. Results {#s0045}
==========

3.1. Baseline characteristics of PAH patient population {#s0050}
-------------------------------------------------------

From July 2009 to June 2012 totally seven newly diagnosed treatment naive patients with PAH and seven healthy controls were enrolled. Demographic data of the patients and healthy controls is presented in [Table 1](#t0005){ref-type="table"}. Among the PAH patients four were with familial PAH, and two with idiopathic PAH and one patient with PAH related to repaired congenital systemic-to-pulmonary shunt. Groups of patients and control were compatible by age and gender. Most subjects in PAH group were WHO functional class II (85.7%). One patient from PAH group had mild arterial hypertension. The mean 6MWD was 361.1 m in PAH group. Main parameters of pulmonary hemodynamics are presented in [Table 1](#t0005){ref-type="table"}. The values of NT-proBNP in PAH patients were significantly increased over the reference range.

3.2. Comparison between PAH patients and control {#s0055}
------------------------------------------------

Groups of PAH patients and control were compatible by age, gender and BMI. PAH subjects had an increased heart rate but no significant difference in blood pressure comparing to healthy volunteers was noted ([Table 1](#t0005){ref-type="table"}). Higher levels of unsaturated FA (oleic (18:1), linoleic (18:2)) in free and phospholipid derived fractions were observed in PAH patients ([Table 2](#t0010){ref-type="table"}). The total amount and majority of the saturated FA within phospholipids were elevated in PAH comparing to control group. Interestingly, that insignificant increase of DHA (22:6) in phospholipids was observed before treatment in PAH. The *ω*6/*ω*3 ratio as well as level of the oxidative stress marker HNE (63.2±21.3 nM *vs.* 48.9±3.2 nM in control) were significantly elevated in PAH ([Fig. 1](#f0005){ref-type="fig"}).

Study of HRV showed marked reduction of the time-domain indexes in supine position in PAH population. SDNN and RMSSD were reduced to 18.3±10.1 ms and 12.7±11.2 ms respectively ([Table 3](#t0015){ref-type="table"}). Prominent lowering in total spectral power (TP 524±469 ms^2^ vs. 2191±975 ms^2^ in control group) was accompanied by marked reduction in the VLF, LF, and HF in PAH patients ([Fig. 2](#f0010){ref-type="fig"}). Sympathetic predominance with higher LF/HF ratio (3.7±2.2 vs*.* 2.7±4.2) in supine position and similar tendency in orthostasis were noted.

3.3. Changes in clinical variables and hemodynamics with sildenafil therapy {#s0060}
---------------------------------------------------------------------------

Twelve weeks of sildenafil therapy administered to newly diagnosed PAH patients caused increase in 6MWD from 361.1±69.4 m to 388.7±60.2 m ([Fig. 3](#f0015){ref-type="fig"}). At the same time, no major changes in the Borg dyspnea index were noted (4.86±1.68 before vs. 4.71±1.70 after treatment, *p*=0.773). Most of the patients remained within the same FC II (*n*=6, 85.7%), and one patient initially in FC III improved to FC II. Some decrease in the peak velocity of the tricuspid regurgitation, the parameter which correlates with the systolic pressure in the pulmonary artery from 66.9±25.3 mmHg to 61.6±25.9 mmHg without major changes in the diameter of the right ventricle were noted during echocardiographic study ([Fig. 3](#f0015){ref-type="fig"}). In general, sildenafil was well tolerated with one out of seven patients reporting headache of mild intensity during treatment.

3.4. Changes in FAs composition and HNE with sildenafil therapy {#s0065}
---------------------------------------------------------------

Initially slightly elevated levels of free saturated and unsaturated FAs in PAH were further increasing reaching statistical significance with sildenafil therapy comparing to control ([Table 2](#t0010){ref-type="table"}). Phospholipid derived saturated and unsaturated FAs tended to decrease over 12 weeks treatment period. The levels of oleic acid (18:1, *cis-*9) and LA (18:1, *cis-*9,12), which were initially elevated, lowered after treatment. Also significant reduction of DHA (22:6, *cis*- 4,7,10,13,16,19) and a tendency to decrease in EPA (20:5, *cis-*5,8,11,14,17) and DPA (22:5, *cis*- 7,10,13,16,19) were noted after sildenafil use ([Table 2](#t0010){ref-type="table"}).

Initially elevated *ω*6/*ω*3 ratio further increased from 7.39±1.38 ng/mL to 7.67±1.69ng/mL with sildenafil therapy and, while high levels of 4-HNE lowered significantly after treatment, falling even below the values observed in control group ([Fig. 1](#f0005){ref-type="fig"}).

3.5. Changes in HRV with sildenafil therapy {#s0070}
-------------------------------------------

HRV parameters in PAH improved after 12 weeks of sildenafil therapy. Time-domain indexes tended to increase but remained lower than in control group ([Table 3](#t0015){ref-type="table"}). Significant increase in TP in supine position was noted but it was still lower comparing to control ([Fig. 2](#f0010){ref-type="fig"}). The treatment associated increase in TP in PAH patients was predominantly on account of the VLF power with its contribution to spectral structure 42% before *vs.* 56% after treatment. Orthostatic test also demonstrated increase in TP on account of the VLF power after sildenafil use but both autonomic components tended to decline further with LF power decreasing from 45% to 28% and HF power from 7% to 4% in spectral structure. At the same time no significant change in LF/HF ratios (3.7±2.2 before vs. 3.6±2.6 after in supine position and 8.0±4.5 before vs. 7.2±3.1 after in orthostasis) was noted.

4. Discussion {#s0075}
=============

Despite major advances in our understanding of the PAH pathobiology the survival of the patients still remains unacceptably low, which substantiates further research in this area. Currently PAH is recognized as a multifactorial disease with metabolic reprogramming and inflammation and taking central stage [@bib66]. Also OS, which is characterized by increased production of reactive oxygen and nitrogen species, uncoupling of eNOS and decreased NO bioavailability with the pathological activation of antiapoptotic and mitogenic pathways leading to cell proliferation and obliteration of the pulmonary vasculature plays an important role [@bib62].

In this study we demonstrated signs of OS on PAH patients by increased level of HNE in blood ([Fig. 1](#f0005){ref-type="fig"}). HNE originates from the oxidation of the ω-6 polyunsaturated FAs, predominantly arachidonic acid, and is involved in the dose-dependent manner into the regulation of various cellular functions including proliferation, differentiation, apoptosis, cell cycle signaling, and modulation of the inflammatory pathways, etc. [@bib7], [@bib78]. The role of high levels of HNE in the pathogenesis of the vascular disease such atherosclerosis, diabetes, neurodegenerative disorders is well defined and its conjugates are frequently regarded as markers of OS [@bib7]. The contribution of HNE to the pathogenesis of PAH may be assumed from its ability to reduce NO bioavailability *via* modulation of its enzymatic productiony. Elevation of peroxinitrite with reduced tetrahydrobiopterin (BH~4~) levels and uncoupled eNOS was shown in bovine aortic endothelial cells pretreated with HNE [@bib72], [@bib73]. In smooth muscle cells HNE was shown to reduce NO production through modulating gene expression and inhibiting transcriptional activation of inducible NO-synthase [@bib27]. Deleterious effects exerted by large amount of HNE on the vasculature also include dysfunction of the endothelial barrier through modulation of the activities of proteins/enzymes by Michael adducts formation, impaired cell--cell communications, inhibition of membrane associated enzymes and development of the pro-inflammatory response [@bib68], [@bib7]. Thus, increased levels of HNE not only confirm presence of OS in PAH patients but also contribute to the pathologic remodeling of the pulmonary vasculature typical of the disease.

Early on, the role of FA and lipid metabolites in the development of PAH have mainly addressed changes in the eicosanoid profile [@bib2], [@bib61], [@bib69], [@bib70] and subsequently provided rationale for targeting the prostacyclin (PGI2) pathway [@bib12]. Nowadays there is accumulating evidence on the role of FAs and their metabolism on the arginine--NOS--NO signaling [@bib43], [@bib56], [@bib79]. Elevated plasma levels of free FAs were shown to modulate endothelium-dependent NO-production and to reduce eNOS activity due to an increase in the mitochondrial ROS production in cultured endothelial cells [@bib26]. Oleic acid, which is abundantly found in human serum, was found to be elevated in PAH patients in present study ([Table 2](#t0010){ref-type="table"}). Interestingly, it was shown to impair pulmonary arterial endothelium-dependent relaxation and endothelium-independent contraction in the canine lung injury model [@bib34]. LA-the major ω6 acid found in western diet which is involved in the endothelial cell activation and potentiation of the inflammatory response was also increased in PAH patients. In the study of Saraswathi et al. exploring the mechanisms of proatherogenic action of LA in endothelial cells the increased Ca^2+^ and peroxynitrite signaling was postulated as an important pathogenetic mechanism of endothelial dysfunction [@bib57]. Thus, contributing potential of LA to the development of obliterative pulmonary angiopathy, which is also characterized by inflammation [@bib30], [@bib54] may result from its proinflammatory action due to the altered NO signaling.

In present study we showed some increase in DPA and DHA in PAH patients. This can be regarded as a compensatory mechanism aimed to promote free radical production, induce antioxidant defense and diminish oxidative damage through prooxidant activity. An increase in PUFAs can also result in improved blood rheology, activation of peroxisomal oxidation and mitochondrial energy function. Supportive evidence of such speculation comes from the facts that levels of HNE and LA, both of which act as the ligands of PPARs receptors and stimulate peroxisomal function were found to be significantly increased in PAH ([Fig. 1](#f0005){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). Recently, the major shift in the metabolic substrate preference with decreased uptake of FAs was demonstrated in the RV in rats with severe pulmonary hypertension [@bib25]. In the model study NOS inhibition caused increase in the levels of arahidonic acid and DHA in the cell membranes due to the stimulation of Δ5 desaturases activity [@bib16]. Whether described changes of the FAs composition contribute to the pulmonary vascular remodeling in PAH warrants further study.

More evidence which proves changes in aerobic metabolism in PAH patients comes from study of HRV, which was markedly reduced ([Table 3](#t0015){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). During the past decades, data has supported the concept of a modulating effect of the aerobic metabolism on HRV [@bib74]. Conditions that are known to be related to OS and inflammation such as ischemic heart disease, diabetes, heart failure were shown to be associated with the reduction of HRV [@bib37], [@bib38], [@bib58]. Low HRV indexes in PAH patients in present study reflect not only alterations of the autonomic balance but also the depth of functional metabolic dysfunction witnessed by changes in biochemical parameters in blood. Moreover, changes in the autonomic indexes derived from assessment of HRV are believed to have independent predictive value on the long-term outcome in heart failure patients [@bib38]. When taking into account that one of the most important clinical syndromes in PAH is right-sided heart failure study of HRV in these patients may be of particular value.

The complex interactions of the [l]{.smallcaps}-arginine-NO-system are presented in [Fig. 4](#f0020){ref-type="fig"}. Interestingly, that most of them are modulated by the flow of ROS. Overproduction of ROS results in reduction in NO bioavailability but their certain amounts are necessary to maintain physiological effects of the NO pathway. The level of acetylcholine, which is known to stimulate enzymatic NO production to the major extend is determined by the rate of alfa-ketoglutarate synthesis in mitochondria and, thus, their functionality [@bib60], [@bib77]. Therefore, optimal intensity of the redox reactions, which precludes maintenance of O~2~/ROS and ATP/ADP balances in mitochondria will promote functioning of the [l]{.smallcaps}-arginine-NO-system. These metabolic changes can be assessed in clinical practice by HRV, especially its autonomic components (HF, LF) in the spectral structure.

Administration of sildenafil for 3 months resulted in significant clinical improvement and increase in the functional capacity of the PAH patients. It beneficially influenced pulmonary hymodynamics as suggested by echocardiographic evaluation and reduced the level of neurohormonal activation marker NT-proBNP. These findings are consistent with the data from the SUPER-1 clinical trial, demonstrating sildenafil to be able to increase the distance walked in six minute and reduce mean pulmonary artery pressure in PAH [@bib19].

By blocking PDE type 5 sildenafil triggers multiple signaling pathways involved into regulation of inflammation, proliferation and apoptosis, and antioxidant defense determining the cross talk between key transcriptional pathways NFkB/Nrf2/HIF1 [@bib29], [@bib41], [@bib49]. This notion is supported by the recent evidence from the model study showing upregulation of Nfr-2 after sildenafil administration [@bib41]. Anti-inflammatory and antioxidant effects of sildenafil were confirmed in our work by decrease in HNE level which became even lower than in control after treatment. Decreased level of HNE may results from improved intensity of the redox reactions and mitochondrial function, which cause activation of the mitochondrial aldehyde dehydrogenase 2-a key enzyme in the detoxification of reactive aldehydes \[[@bib8], [@bib24]\] and, thus, promote cardioprotective effect of sildenafil.

Reduction of the OS signs was accompanied by decrease in unsaturated FAs, especially oleic, linoleic in phospholipids, which may be due to inhibition of lipid peroxidation or their better utilization for the maintenance of the redox balance. The level of DHA decreased significantly after sildenafil therapy which is suggestive about improved structural integrity of the membranes and better functionality of the membrane bound enzymes, receptors, and ion channels. Activity of mitochondrial K^+^~ATP~ and BK~Ca~ channels is closely related to activation of NO/CO/H~2~S pathways [@bib51], [@bib52], [@bib53], which was also described with sildenafil use [@bib41]. The function of these mitochondrial membrane-bound channels is known to be coupled with the activity of the autonomic nervous system.

In present study administration of sildenafil caused increase in main time-domain index SDNN, which is informative about autonomic control in general, and both pNN50 and RMSSD, which reflect parasympathetic activity ([Table 3](#t0015){ref-type="table"}). Significant increase in total spectral power after sildenafil use was accompanied by increase in all spectral components but predominantly VLF suggestive about neurohormonal activation without major changes in LF/HF balance. Similar tendencies were observed in orthostasis. Three month of sildenafil therapy did not restore HRV and, thus, did not provide complete recovery of the functional metabolic disorders in PAH. Increase in free FAs in blood after treatment may contribute to further inhibition of eNOS [@bib26], [@bib57] and confirms incomplete elimination of the oxidative damage, which was reflected by VLF predominance and persistent sympathetic activation in spectral structure of HRV.

It is worth noting that maintenance of NO flow only on account of the inhibition of PDE type 5 on the long run will result in overstimulation of PKG and associated various signaling cascades, which can lead to excessive production of NO and subsequent formation of peroxinitrite and OS persistence [@bib65]. On the other hand, hypoxia and acidosis accompanying OS contribute to production of NO from the alternative sources, namely, nitrite reductase pathway involving a wide range of enzymes such as xanthine oxidase, cytochrome oxidase etc., which may further facilitate OS [@bib35], [@bib82]. In our opinion, such metabolic disturbances can be overcome through mild activation of free radical reactions, which will promote fluctuations of different ROS and oxygen [@bib58], [@bib74] and will help to eliminate hypoxia, signs of OS and to normalize function of the oxygen dependent enzymes, including NOS. Moreover, nonenzymetic production of NO in the NO/NO~2~/NO~3~ cycle can be activated. Such approach when applied to treatment is described as development of hormetic reaction, which can be achieved through many prooxidant influences [@bib15], [@bib40], [@bib59], with the most well documented being PUFA supplementation.

The beneficial effects of the dietary omega 3 PUFAs on the cardiovascular health are well described [@bib18], [@bib33], [@bib80], while the evidence of their role in PAH is rather limited. Recently, the anti-inflammatory potential of PUFAs was shown to contribute to reverse remodeling of pulmonary vasculature in the experimental studies. Morin et al. showed that administration of monoacylglyceride residues of DPA (22:5) lowered levels of arachidonic acid in blood and tissue samples and reduced NF-kB, IL-8 and p38 MAPK activation, thus, causing a decrease in pulmonary artery pressure and an improvement of the right ventricular hypertrophy in rat [@bib46]. In the in vitro model of human pulmonary artery overactivity induced by endothelin-1, IL-6, TNF-α a trihydroxylated DHA derivative resolvin D1 was able to reverse hyperresponsiveness caused by proinflammatory treatments [@bib30]. EPA and DHA have been reported to prevent pressure-overload induced cardiac fibrosis [@bib9], which may be also of particular importance in PAH.

5. Conclusions {#s0080}
==============

Nowadays, although PAH patients report clinical and hemodynamic improvement with sildenafil monotherapy the prognosis of the disease remains serious and search for the ways to improve treatment efficacy continues. PAH is increasingly recognized as a metabolic disease associated with OS [@bib1], [@bib31], [@bib4], which was confirmed in present study. Patients with PAH were characterized by increased HNE in blood, changes in the FAs composition with high levels of saturated and unsaturated (oleic, LA, DHA) acids in phospholipids as well as reduced HRV with sympathetic predominance. Sildenafil improved clinical status and pulmonary hemodynamics in PAH subjects, reduced signs of OS, modulated FAs composition lowering oleic, LA, DPA, DHA in phospholipids, which is suggestive about its antioxidant and anti-inflammatory action. That was accompanied by some improvement of HRV indexes with increase in total spectral power on account of the neurohumoral regulatory component. At the same time, incomplete recovery of the functional metabolic disorders in PAH patients may be assumed from the persistent increase in free FAs in serum, reduced HRV with sympathetic predominance in the spectral structure after treatment comparing to control group. The efficacy of the sildenafil therapy may be improved through mild stimulation of redox reactions and formation of the hormetic response, which facilitates not only enzymatic but also nonenzymetic NO production. Providing options to increase the efficacy of PAH specific treatment would open new possibilities for the patients once described to live in "the kingdom on near death".
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![Changes in the *ω*6/*ω*3 ratios and 4-HNE in PAH patients with sildenafil therapy. Note: data presented as mean±SEM; *ω*6/*ω*3 ratio was calculated as (18:2+20:4)/(22:5+22:6+20:5).](gr1){#f0005}

![Changes in frequency-domain HRV indexes in PAH patients with sildenafil therapy. Note: A-supine position; B-orthostatic test; data presented as mean±SD; HRV-heart rate variability; TP --total power; VLF -- very low frequency; LF- low frequency; HF -- high frequency.](gr2){#f0010}

![Changes in 6MWT, echocardiographic indexes and NT-proBNP with sildenafil therapy. Note: tricuspid valve (TV) pressure gradient by echocardiography improved significantly after 12 weeks of sildenafil therapy. Also tendency to reduction of the right ventricle (RV) size was noted. Increase in the distance in 6-min walk test (6-MWT) was associated with the reduction in the NT-proBNP level. Data presented as mean±SD, \**p*\<0.05 vs. baseline.](gr3){#f0015}

![Metabolic interactions of the [l]{.smallcaps}-arginine-NO pathway during sildenafil therapy. The bioavailability of NO is influenced by a complex of factors. Oxidative stress, hypoxia, and reduced intensity of redox reactions are accompanied by increased levels of free fatty acids mostly oleic, linoleic, and docosahexanoic (DHA) with subsequent elevation of hydroxynonenal (HNE), which impairs the activity of endothelial NO synthase (eNOS) prompting NO deficiency state. Moreover, elevated levels of HNE contribute to depletion of tetrahydrobiopterin (BH4) and, thus, can mediate uncoupling and generation of superoxide [@bib72]. Increased HNE is also associated with accumulation of the endogenous eNOS inhibitor asymmetric dimethylarginine [@bib10]. Moreover, HNE was demonstrated to suppress iNOS and inhibit NO formation due to activation of Nrf-2 [@bib22]. That notion is further supported by a study demonstrating HNE directly forming adducts with transcriptional inhibitor Keap-1[@bib44]. Sildenafil improves NO signaling by blocking phosphodiesterase type 5 and increasing intracellular cGMP level leading to relaxation of smooth muscle cells, reducing vascular remodeling and vasoconstriction. At the same time, long term potentiation of [l]{.smallcaps}-arginine-NO-system by sildenafil may trigger hyperactivation of various cGMP-dependent signaling pathways, excessive prooxidant activity and exhaustion of antioxidant potential, which results in distorted feedback regulation. Such metabolic derangements are reflected by reduced heart rate variability and worsening of its spectral structure. The efficacy of long-term sildenafil therapy may be improved by concomitant stimulation of free radical reactions (FRR), maintenance of pO~2~ and development of mild prooxidant activity, which can be achieved with administration of intermittent hypoxic training, use of flavonoids or various supplements used as the sources of PUFAs (fish, plant oils, etc.).](gr4){#f0020}

###### 

Characteristics of patients with PAH and healthy controls.

Table 1.

  **Variable**                                          **PAH patient, *n*=7**   **Control, *n*=7**                                   ***p* Value**
  ----------------------------------------------------- ------------------------ ---------------------------------------------------- ---------------
  Age,years                                             30.9±7.3                 30.6±4.2                                             0.930
  Gender, M/F                                           3/4                      3/4                                                  1.000
  FC, II/III                                            6/1                      \-                                                   \-
  BMI, kg/m^2^                                          26.3±6.7                 24.8±3.4                                             0.611
  Heart rate, bpm                                       84.6±8.6                 69.3±6.2                                             0.012
  Syst. BP, mmHg                                        120.8±10.7               117.8±7.6                                            0.590
  Diast. BP, mmHg                                       82.8±11.7                79.1±7.4                                             0.530
  Hypertension, *n* (%)                                 1 (14.3)                 \-                                                   \-
  6-MWT, m                                              361.1±69.4               \> 580 male[\*](#tbl1fnStar){ref-type="table-fn"}    \-
  \> 500 female[\*](#tbl1fnStar){ref-type="table-fn"}                                                                                 
  NT-proBNP, pg/ml                                      3101±1952                \< 85.8 male[\*](#tbl1fnStar){ref-type="table-fn"}   \-
  \< 130 female[\*](#tbl1fnStar){ref-type="table-fn"}                                                                                 
  mPAP, mmHg                                            58.9±16.3                7-19[\*](#tbl1fnStar){ref-type="table-fn"}           \-
  PAWP, mmHg                                            9.5±3.1                  5-13[\*](#tbl1fnStar){ref-type="table-fn"}           
  PVR, dyn sec m^2^/cm^5^                               1052±494                 11-99[\*](#tbl1fnStar){ref-type="table-fn"}          \-
  CO, L/min                                             3.46 (3.22, 4.16)        4.4--8.4[\*](#tbl1fnStar){ref-type="table-fn"}       \-
  CI, L/min/m^2^                                        2.00 (1.88, 2.27)        2.6--4.2[\*](#tbl1fnStar){ref-type="table-fn"}       \-
  FEV1, %                                               79.0±6.5                 \-                                                   \-
  VC, %                                                 76.0±7.5                 \-                                                   \-

Data are presented as mean±SD or median (interquartile range).

Values were taken from [@bib50]; PAH=pulmonary arterial hypertension; M/F=male/female; FC=functional class; BMI=body mass index; 6MWT=6-min walk test; NT-proBNP=N-terminal pro-brain natriuretic peptide; mPAP=mean pulmonary arterial pressure; PAWP -- pulmonary artery wedge pressure; PVR=pulmonary vascular resistance; CO=cardiac output; CI=cardiac index; FEV1 -- forced expiratory volume in 1 s; VC- vital capacity.

###### 

Changes in the fatty acids composition associated with sildenafil therapy in PAH

Table 2.

  **Fatty acids**                                **PAH**                                          **Control**                                        
  ---------------------------------------------- ------------------------------------------------ -------------------------------------------------- ------------
  **Free FA**                                                                                                                                        
  ***Saturated***                                                                                                                                    
  Palmitic acid, (16:0)                          1.40±0.26                                        1.64±0.18[\#](#tbl2fna2){ref-type="table-fn"}      1.08±0.08
  Stearic acid, (18:0)                           0.85±0.13                                        1.22±0.08[\#](#tbl2fna2){ref-type="table-fn"}      0.98±0.09
   Sum                                           2.24±0.16                                        2.85±0.25[\#](#tbl2fna2){ref-type="table-fn"}      2.05±0.17
  ***Unsaturated***                                                                                                                                  
  Palmitoleic acid, (16:1, *cis-*9)              0.11±0.05                                        0.13±0.02[\#](#tbl2fna2){ref-type="table-fn"}      0.05±0.01
  Oleic acid, (18:1, *cis-*9)                    0.51±0.07                                        1.13±0.28[\#](#tbl2fna2){ref-type="table-fn"}      0.43±0.06
  Linoleic acid, (18:2, *cis-*9,12)              0.83±0.31                                        1.14±0.24[\#](#tbl2fna2){ref-type="table-fn"}      0.36±0.14
   Sum                                           1.45±0.33                                        2.40±0.52[\#](#tbl2fna2){ref-type="table-fn"}      0.83±0.20
    **Phospholipids**                                                                                                                                  
  ***Saturated***                                                                                                                                    
  Palmitic acid, (16:0)                          46.30±1.68[\#](#tbl2fna2){ref-type="table-fn"}   44.71±2.13                                         42.18±2.06
  Stearic acid, (18:0)                           16.73±0.98[\#](#tbl2fna2){ref-type="table-fn"}   15.38±1.43                                         13.04±1.73
  Arachidic acid, (20:0)                         0.18±0.01[\#](#tbl2fna2){ref-type="table-fn"}    0.18±0.02[\#](#tbl2fna2){ref-type="table-fn"}      0.12±0.02
  Behenic acid, (22:0)                           0.19±0.04                                        0.25±0.05^a^                                       0.12±0.08
   Sum                                           63.40±2.70[\#](#tbl2fna2){ref-type="table-fn"}   60.53±3.60                                         55.47±3.41
  ***Unsaturated***                                                                                                                                  
  Palmitoleic acid, (16:1, *cis-*9)              1.57±0.07                                        1.47±0.06                                          1.41±0.08
  Oleic acid, (18:1, *cis-*9)                    12.06±1.15[\#](#tbl2fna2){ref-type="table-fn"}   10.62±0.64                                         9.38±0.55
  Linoleic acid, (18:2, *cis-*9,12)              26.02±1.78[\#](#tbl2fna2){ref-type="table-fn"}   22.88±2.81                                         21.31±3.06
  Arachidonic acid, (20:4, *cis-*5,8,11,14,17)   20.93±1.48                                       19.18±1.25                                         19.33±2.46
  Eicosapentanoic acid,                                                                                                                              
  (20:5, *cis-*5,8,11,14,17)                     1.58±0.08                                        1.53±0.10                                          1.76±0.22
  Nervonic acid, (24:1, *cis*-15)                0.55±0.04[\#](#tbl2fna2){ref-type="table-fn"}    0.60±0.06[\#](#tbl2fna2){ref-type="table-fn"}      0.39±0.04
  Docosapentanoic acid,                                                                                                                              
  (22:5, *cis*- 7,10,13,16,19)                   0.92±0.12                                        0.82±0.11                                          0.81±0.18
  Docosahexanoic acid,                                                                                                                               
  (22:6, *cis*- 4,7,10,13,16,19)                 3.90±0.17                                        3.33±0.34[\*](#tbl2fnStar1){ref-type="table-fn"}   3.32±0.86
   Sum                                           67.52±4.0                                        60.42±3.60                                         57.71±6.15

**Note**: Data are presented as mean±SEM in ng/mL;

difference significant between PAH before or after treatment and control group, *p*\<0.05.

difference significant before and after sildenafil, *p*\<0.05;

###### 

Changes in HRV indexes in PAH patients with sildenafil therapy

Table 3.

  **Parameter**         **PAH**                                       **Control**                                               
  --------------------- --------------------------------------------- --------------------------------------------- ----------- -----------
  **Supine position**   SDNN, ms                                      18.3±10.1[a](#tbl3fna){ref-type="table-fn"}   32.0±16.5   44.3±9.0
  RMSSD, ms             12.9±11.2[a](#tbl3fna){ref-type="table-fn"}   21.4±23.7[a](#tbl3fna){ref-type="table-fn"}   36.5±11.7   
  pNN50,%               1.66±3.62                                     6.9±14.4                                      13.6±12.0   
  LF/HF                 3.7±2.2                                       3.6±2.6                                       2.7±4.2     
  **Orthostasis**       SDNN, ms                                      40.9±16.5                                     45.9±17.0   45.8±17.7
  RMSSD, ms             19.4±16.2                                     14.1±7.1                                      19.6±9.8    
  pNN50,%               3.92±8.05                                     1.2±1.4                                       3.0±3.6     
  LF/HF                 8.0±4.5                                       7.2±3.1                                       5.8±3.3     

**Note:** data presented as mean ± SD;

Difference significant comparing to control group.
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